Cold-chain provider Shanghai Shengsheng joins pharma IPO hopefuls
China’s biggest supplier of temperature-controlled services for the drug sector has renewed a Hong Kong listing plan, raising questions with hefty pre-IPO payouts Key Takeaways: Turnover has grown steadily, driven…
Biokin’s world-first bispecific ADC hits milestones, speeding commercialization
Iza-bren was approved for recurrent or metastatic esophageal squamous cell carcinoma, after receiving earlier approval to treat nasopharyngeal carcinoma Key Takeaways: New approvals for Biokin’s Iza-bren highlight the rise of…
MicroPort MedBot serves up inaugural profit on booming exports
The medical robot maker expects to report a profit of 28 million yuan to 40 million yuan for the first half of 2026, reversing years of losses Key Takeaways: MicroPort…
Joinn’s profit figures spark market outbreak of “monkey fever”
Projected earnings at the drug research company have been inflated by the soaring value of research monkeys, but the on-paper gains may not be sustainable Key Takeaways: Joinn Laboratories uses…
Insilico revenue soars above $100 million on AI drug partnerships
The developer of the world’s first end-to-end AI drug has projected a big leap in half-year earnings, driven by lucrative collaborations with multinationals Key Takeaways: Insilico expects to power into…
Gushengtang steps up TCM buying spree, doubling down in Beijing
The healthcare company has announced five acquisitions in the past two weeks to shore up growth and fend off competition in the traditional Chinese medicine market Key Takeaways: Gushengtang is…
Drug setback leaves Ascletis with an all-in bet on weight loss
The company’s two core hepatitis drugs were dropped from China’s state insurance scheme on July 1, effectively wiping out the remains of its legacy drug sales Key Takeaways: The company…
